Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers. The purpose of this study was to examine the expression of EZH2 and analyze its relationship with the clinicopathological features of human gastric cancers. The expression levels of EZH2 mRNA and protein were examined in 13 gastric cancer cell lines and 83 surgically removed human gastric cancer tissues.
Summary
Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers. The purpose of this study was to examine the expression of EZH2 and analyze its relationship with the clinicopathological features of human gastric cancers. The expression levels of EZH2 mRNA and protein were examined in 13 gastric cancer cell lines and 83 surgically removed human gastric cancer tissues.
Immunohistochemical analysis of the 83 tissue samples and corresponding non-cancerous gastric mucosa showed that EZH2 was more highly expressed in the cancerous than in the non-cancerous tissues, and the expression levels of EZH2 were highly correlated with tumor size, depth of invasion, vessel invasion, lymph node metastasis and clinical stages. Univariate analysis of survival rate calculated by the Kaplan-Meier method revealed that gastric cancer patients with high-level EZH2 expression had poorer prognosis than those expressing no or low levels of EZH2 (P = 0.0271).
These findings suggest that overexpression of EZH2 may contribute to the progression and oncogenesis of human gastric cancers, and thus immunohistochemical study of EZH2 expression may serve as a new biomarker for predicting the prognosis of gastric cancers.
Introduction
Although gastric cancer has gradually decreased in prevalence, it still accounts for a large portion of the cancer-related deaths in Japan. The most informative prognostic factor is the tumor stage, which involves both the depth of invasion and the extent of metastasis. The size and histologic type of the tumor may also be useful factors.
Despite the complexity of stomach carcinogenesis, a number of molecular studies have been performed to search for the additional prognostic factors. As a result, several proteins, such as transforming growth factor alpha (TGFα), epidermal growth factor receptor (EGFR), c-met, c-erbB2, cyclin E, p27 Kip1 and CDC25B, have been identified as markers of the malignancy of gastric cancer.
(1-3)
The search for molecular factors that are highly correlated with prognosis may lead to the discovery of factors that can help to predict not only patient survival, but also the tumor response to specific anticancer drugs. One new marker that has potential for cancer screening and can be a predictor of patient survival is enhancer of zeste homolog 2 (EZH2).
EZH2, also called histone lysine methyltransferase (HKMT) was cloned as one of the polycomb group genes.
The function of EZH2 is to catalyze the subunit of the polycomb repressor complex by methylating lysine 9 and 27 of histon H3. (5) (6) (7) (8) Although EZH2 which by itself lacks enzyme activity, EZH2 is assumed to associate with specific polypeptides present in the polycomb repressive complexes 2 and 3 (PRC2/3), constructing EZH2 complex to work as a repressor gene in various organs. (5) (6) (7) (8) (9) (10) (11) (12) Recently, close correlation between overexpression of EZH2 and progression of prostate cancer was reported by Varambally et al. in a study using cDNA microarray analysis. (13) An association of EZH2 overexpression with the biological malignancy of tumors has also been reported for several other cancers, breast cancer, hepatocellular carcinoma, bladder carcinoma and lymphomas. (10, (14) (15) (16) (17) (18) (19) (20) (21) (22) In the present study, we examined the mRNA and protein expression of EZH2 in human gastric cancer cell lines. We then conducted EZH2 immunohistochemical analysis of human gastric cancer tissues and analyzed the relationship between EZH2 expression and clinicopathological factors. Furthermore, the association between EZH2 expression and the prognosis of gastric cancer patients was investigated.
Materials and Methods
Cell cultures. Thirteen cell lines derived from human gastric carcinoma were used. Eight gastric cancer cell lines of the HSC series (HSC-57, tubular adenocarcinoma; HSC-42, HSC-58 and HSC-59, poorly differentiated adenocarcinoma;
HSC-40, HSC-44, HSC-45 and HSC-60, signet ring cell carcinoma) and SH101-P4
(tubular adenocarcinoma) were established by one of the authors (K.Y.). (23, 24) Three cell lines of the MKN series (MKN-1, adenosquamous cell carcinoma; MKN-7 and MKN-74, tubular adenocarcinoma) were provided by Dr. T. Suzuki (Fukushima Medical University, Fukushima). (25, 26) The TMK-1 cell line (poorly differentiated adenocarcinoma) was a gift from Dr. W. Yasui (Hiroshima University, Hiroshima). (27) Mann-Whitney U-tests. The survival rate curves were drawn according to the Kaplan-Meier method, and differences between the curves were analyzed by applying 8 the log-rank test. The date of resection was considered day zero. The terminal event for cancer-related survival was death attributable only to cancer. The significance level was set at 5 % for each analysis.
Results

Expression of EZH2 in human gastric cancer cell lines.
We first examined the expression of EZH2 in 13 gastric cancer cell lines and non-cancerous gastric mucosa at the mRNA and protein levels using quantitative RT-PCR and Western blot analyses, respectively. All of the 13 gastric cancer cell lines expressed some level of EZH2 mRNA (Fig. 1a) . In 8 EZH2 protein expressions in these 13 cell lines and non-cancerous gastric mucosa were determined by Western blot analysis using the anti-EZH2 antibody to confirm the specificity of the antibody (Fig. 1b) . As expected, each cell line showed a band with 100 kDa molecular weight whose intensity corresponded to its expression level of EZH2 mRNA. (Fig. 2n, o) . Correlation of EZH2 expression levels with patient survival after surgery.
Finally, we performed a prognostic study in 64 patients who received curative surgery from 1999 to 2002 and were followed up for 1 to 52 months. Seventeen of these patients died from gastric cancer at between 2 and 30 months (mean 11.4 months).
The mean follow-up time of the remaining 47 cases was 20 months. The results of the univariate analysis of survival rate calculated by the Kaplan-Meier method are shown in Table 2 and Fig. 3 . The calculation showed that the size of the tumor, depth of invasion, lymph node metastasis, distant metastasis, stage, and level of EZH2 expression were associated with an increased risk of death ( Table 2 ). As shown in Fig.   3a , cases with gastric cancer expressing high levels of EZH2 had a worse prognosis than those expressing no or low levels of EZH2 (P = 0.0271). In order to compare the effect of EZH2 expression and the histologic type of gastric cancer on the prognosis, we divided the cases into two groups: cohesive type (papillary adenocarcinoma, tubular adenocarcinoma, solid-type poorly differentiated adenocarcinoma and mucinous 12 adenocarcinoma) and non-cohesive type (non-solid type poorly differentiated adenocarcinoma, signet-ring cell carcinoma). The survival rate was calculated for each group by the Kaplan-Meier method, and the results are shown in Fig. 3b . No statistically significant differences were observed between the two types (P = 0.7975).
In addition, although cases of gastric cancer exhibiting high levels of EZH2 expression tend to have poorer prognosis from those with low levels of EZH2 expression when the T1 cases were excluded from Fig. 3a , a significant statistical difference was not observed between them ( Fig. 3c , P = 0.6220).
Discussion
The overexpression of EZH2 in advanced prostate cancer in comparison with benign prostate tissues and organ-confined tumors was reported using cDNA microarray analysis. (13) Moreover, because high EZH2 protein levels have been strongly associated with the aggressiveness and patient outcome of prostate cancer, it was proposed that the dysregulation of EZH2 expression might promote the malignant transformation of normal cells involving DNA transcription. (10, 11, 13, 14, 29, 30) An association between EZH2 overexpression and the biological malignancy of the tumor has also been reported for breast cancer, lymphoma, hepatocellular carcinoma and bladder carcinoma. (14) (15) (16) (17) (18) (19) (20) (21) (22) In the present study, the expression levels of EZH2 protein determined by Western blot analyses were in good agreement with those of EZH2 mRNA determined by quantitative real-time RT-PCR in 13 gastric cancer cell lines. These results suggested that expression of the EZH2 protein was regulated primarily in the transcriptional process, and we decided to use this anti-EZH2 antibody in the following immunohistochemical study. Immunohistochemical analysis was carried out to investigate whether overexpression of EZH2 was actually reflected in the gastric cancer specimens taken surgically. We found that 56.6% (47 out of 83 cases) of gastric cancer tissues showed high expression of EZH2, which agreed with the previously reported frequency (44%, 8 out of 18 cases) by tissue microarray analysis. (31) In the tumor cells, EZH2 immunoreactivity was mainly located in the nucleus, while some of the sections 14 showed cytoplasmic staining with nuclear dominant patterns, which is also in good agreement with the previously reported results on breast cancer and prostate cancer. (13, 14, 30) To examine the clinical use of EZH2 protein as a marker of gastric cancer progression, the associations between EZH2 and clinicopathological factors were evaluated. High levels of EZH2 expression in gastric cancer tissues were significantly associated with several clinicopathological factors i.e., tumor size, depth of invasion, vessel invasion, lymph node metastasis and clinical stages. These results strongly suggest that the association of EZH2 protein expression to tumor growth and cell invasion in gastric cancer, so as reported on prostate cancer, breast cancer, bladder carcinoma and lymphomas. The implications of EZH2 in tumor growth and cell invasion may be explained by the existence of several target genes of EZH2. It is known that EZH2
works to suppress several genes, and a number of the target genes of EZH2 have been revealed by DNA microarrays. (13, 32) These include not only cell proliferation genes, but also metastasis-suppressing genes such as Rho GTPase-activating protein 1. (13) Most of the preceding studies described the role of nuclear EZH2 in tumor progression. In addition to nuclear EZH2, we noted the expression of cytosolic EZH2, since cytosolic EZH2 has been recently reported to play a role in actin polymerization. (33) Interestingly, we found that gastric cancer cells forming intravascular tumor emboli showed very strong cytosolic EZH2 immunoreactivity.
This phenomenon may support the idea that the cells expressing cytoplasmic EZH2 have higher motility and therefore a greater ability to invade via the actin polymerization pathway.
In consequence, the results in this study showed there were no correlation between distant metastasis and cytosolic EZH2 expression. We speculated that the mechanism by which EZH2 increases the ability to move and invade is due to its property of polymerizing actins, but this property is not sufficient for establishment of distant metastasis because of improper changes in actin polymerizing balance. To establish the distant metastasis, actin need to be not only polymerized but also severed. (34) This notion is reminiscent of gelsolin, an actin-binding protein that regulates dynamic changes in the actin cytoskeleton by severing actin filaments into smaller pieces.
Gelsolin by itself does not associated with lymph node metastasis, but becomes prognostic factor when it coexists with erbB2/EGFR, receptors promoting actin polymerization. (35) The factors associate that cooperate with EZH2 in actin dynamics are not understood yet. Evaluation of such factors and EZH2 in a pair would be useful for predicting distant metastasis.
Though there was no relation between distant metastasis and cytoplasmic EZH2 expression in the present study (data not shown), the survival rate calculated by Kaplan-Meier analysis revealed a significant correlation between nuclear EZH2 expression and prognosis. Several studies have been reported that the histologic type of gastric cancers appeared to influence their prognosis. (36) (37) (38) (39) Because cancer cells having a lesser ability to aggregate (non-cohesive type) are generally regarded as a type of gastric cancer with highly malignant potential in comparison with those having greater ability to aggregate (cohesive type), we wondered whether high levels of EZH2 expression in different histological types of cancer consist with the correlation between high EZH2 expression and clinically malignant phenotypes of gastric cancers. Our analysis using the Kaplan-Meier method demonstrated a significant correlation between EZH2 expression and prognosis, but did not demonstrate a correlation between histologic type and prognosis. Additionally, because T1-early gastric cancer-cases may enhance the patients' outcome, we calculated the prognosis without the T1 cases.
However, the number of the cases was not enough to give confidence in the obtained results; there was a slight tendency for poorer prognosis in the group of high levels of EZH2 expression.
The pathologic staging is also known as useful determinant of patient prognosis after curative surgery for gastric cancer and a key factor effecting the choice of postoperative strategy. (40) (41) (42) (43) The present results support the notion that EZH2 expression could be used to screen patient with aggressive gastric cancer and poor prognosis. Therefore, clinical therapy can be planned along with EZH2 expression level even though there was no metastasis detected at the time of surgery or primary diagnosis.
In summary, the present study showed for the first time the high correlation of EZH2 expression with poorer prognosis and the applicability of screening EZH2 expression as a prognostic determinant. Furthermore, EZH2 might be a molecular target in the clinical treatment of gastric cancer; accordingly, further studies will be 17 required to confirm these findings. were analyzed by χ 2 -test and P < 0.05 were considered to be significant. ‡ Tumor size and age were divided into two groups according to the median value. § Histological type, depth of invasion, stage, lymphatic invasion, venous invasion and extent of lymph node metastasis were determined according to the Japanese Classification of Gastric Cancer (28) ; pap, papillary adenocarcinoma; tub, tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma; muc, mucinous adenocarcinoma. 
